BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30730273)

  • 1. Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.
    Abdel-Rahman O; Morris D
    Immunotherapy; 2019 Feb; 11(3):149-153. PubMed ID: 30730273
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 6. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy].
    Sun W; Zhou J; Zhou J
    Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):36-42. PubMed ID: 33478189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
    El-Osta H; Jafri S
    Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
    Morgensztern D; Herbst RS
    Clin Cancer Res; 2016 Aug; 22(15):3713-7. PubMed ID: 27252413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy for lung cancer].
    Ostoros G
    Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy combinations emerging in non-small-cell lung cancer.
    Chao YL; Pecot CV
    Immunotherapy; 2018 Jun; 10(8):627-629. PubMed ID: 29882690
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
    Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
    Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.